RecruitingNCT07174947
Fluoxetine with immunotherapy in liver and bile duct cancer
About this title
Read the official source — NCT07174947Medication studyAges 18–80ChinaDepression
Understand this study
Who could participate?
Listed age limits: 18 years to 80 years.
- Listed locations
- WenzhouSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: October 1, 2025
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 240
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- China
- Age range
- From 18 Years to 80 Years
- Official registry ID
- NCT07174947
- Official title
Show the full official title
SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depression and Anxiety: A Randomized Controlled Clinical Trial
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Wenzhou
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is First Affiliated Hospital of Wenzhou Medical University, a university.
Does this study involve medication?
Yes. The study involves medication, including Fluoxetine (drug) and Placebo.
Who can participate?
Listed age limits: 18 years to 80 years.
Is this study still recruiting?
The registry lists this study as recruiting.
